tert-butyl (2S)-2-(5-(6-(5-cyclopropylthiophen-2-yl)-1-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6H-benzo-[5,6][1,3]oxazino[3,4-a]indol-10-yl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate | 1620454-92-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: tert-butyl (2S)-2-(5-(6-(5-cyclopropylthiophen-2-yl)-1-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6H-benzo-[5,6][1,3]oxazino[3,4-a]indol-10-yl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate
• 英文别名: tert-butyl (2S)-2-[5-[6-(5-cyclopropylthiophen-2-yl)-1-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6H-indolo[1,2-c][1,3]benzoxazin-10-yl]-1H-imidazol-2-yl]pyrrolidine-1-carboxylate
• CAS: 1620454-92-3
• 化学式: C₄₀H₄₄BFN₄O₅S
• 分子量: 722.689
• InChiKey: XAMJZBMEYFKWTN-FIMWSPJOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.09
• 重原子数：
  52
• 可旋转键数：
  7
• 环数：
  9.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  119
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  tert-butyl (2S)-2-(5-(6-(5-cyclopropylthiophen-2-yl)-1-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6H-benzo-[5,6][1,3]oxazino[3,4-a]indol-10-yl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 在 盐酸 、 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 sodium carbonate 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 生成 methyl ((S)-2-((S)-2-(5-((S)-6-(5-cyclopropylthiophen-2-yl)-1-fluoro-3-(2-((S)-1-((methoxycarbonyl)-L-valyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)-6H-benzo[5,6][1,3]oxazino[3,4-a]indol-10-yl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-1-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-oxoethyl)carbamate
  参考文献：
  名称：

  Discovery of MK-6169, a Potent Pan-Genotype Hepatitis C Virus NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Substitutions

  摘要：

  We describe the discovery of MK-6169, a potent and pan-genotype hepatitis C virus NS5A inhibitor with optimized activity against common resistance-associated substitutions. SAR studies around the combination of changes to both the valine and aminal carbon region of elbasvir led to the discovery of a series of compounds with substantially improved potency against common resistance-associated substitutions in the major genotypes, as well as good pharmacokinetics in both rat and dog. Through further optimization of key leads from this effort, MK-6169 (21) was discovered as a preclinical candidate for further development.

  DOI：

  10.1021/acs.jmedchem.7b01927
• 作为产物：
  描述：

  2-(5-bromoindolin-2-yl)-5-chloro-3-fluorophenol 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 tris-(dibenzylideneacetone)dipalladium(0) 、 potassium acetate 、 sodium carbonate 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三氟乙酸 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 、 甲苯 、 乙腈 为溶剂， 反应 24.0h， 生成 tert-butyl (2S)-2-(5-(6-(5-cyclopropylthiophen-2-yl)-1-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6H-benzo-[5,6][1,3]oxazino[3,4-a]indol-10-yl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate
  参考文献：
  名称：

  Discovery of MK-6169, a Potent Pan-Genotype Hepatitis C Virus NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Substitutions

  摘要：

  We describe the discovery of MK-6169, a potent and pan-genotype hepatitis C virus NS5A inhibitor with optimized activity against common resistance-associated substitutions. SAR studies around the combination of changes to both the valine and aminal carbon region of elbasvir led to the discovery of a series of compounds with substantially improved potency against common resistance-associated substitutions in the major genotypes, as well as good pharmacokinetics in both rat and dog. Through further optimization of key leads from this effort, MK-6169 (21) was discovered as a preclinical candidate for further development.

  DOI：

  10.1021/acs.jmedchem.7b01927

文献信息

• [EN] THIOPHENE- SUB STITUED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES<br/>[FR] COMPOSÉS TÉTRACYCLIQUES À SUBSTITUTION THIOPHÈNE ET LEURS PROCÉDÉS D'UTILISATION POUR LE TRAITEMENT DES MALADIES VIRALES
  申请人：MERCK SHARP & DOHME

  公开号：WO2014110688A1

  公开（公告）日：2014-07-24

  Disclosed are novel Thiophene-Subsituted Tetracyclic Compounds of Formula (I). And pharmaceutically acceptable salts thereof, wherein A, A', R2, R3, R4 and R5 are as defined herein. The compositions comprising at least one Thiophene-Subsituted Tetracyclic Compounds, and methods of using the Thiophene-Subsituted Tetracyclic Compounds for treating or preventing HCV infection in a patient are also disclosed.

  本发明涉及一种新颖的式(I)的噻吩取代四环化合物，以及其药学上可接受的盐，其中A、A'、R2、R3、R4和R5如本文所定义。还公开了包含至少一种噻吩取代四环化合物的组合物，以及使用这些噻吩取代四环化合物治疗或预防患者HCV感染的方法。
• [EN] THIOPHENE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES<br/>[FR] COMPOSÉS TÉTRACYCLIQUES À SUBSTITUTION THIOPHÈNE ET LEURS MÉHODES D'UTILISATION POUR LE TRAITEMENT DE MALADIES VIRALES
  申请人：MERCK SHARP & DOHME

  公开号：WO2014110706A1

  公开（公告）日：2014-07-24

  Thiophene-substituted tetracyclic compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein A, A', R2, R3, R4 and R5 are as defined herein. The compositions comprising at least one thiophene-substituted tetracyclic compound, and methods of using the thiophene-substituted tetracyclic compounds for treating or preventing HCV infection in a patient are also provided.

  式(I)的噻吩取代四环化合物及其药用可接受的盐，其中A、A'、R2、R3、R4和R5如本文所定义。还提供了包含至少一种噻吩取代四环化合物的组合物，以及使用这些噻吩取代四环化合物治疗或预防患者HCV感染的方法。
• Discovery of MK-6169, a Potent Pan-Genotype Hepatitis C Virus NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Substitutions
  作者：Wensheng Yu、Ling Tong、Oleg Selyutin、Lei Chen、Bin Hu、Bin Zhong、Jinglai Hao、Tao Ji、Shuai Zan、Jingjun Yin、Rebecca T. Ruck、Stephanie Curry、Patricia McMonagle、Sony Agrawal、Laura Rokosz、Donna Carr、Paul Ingravallo、Karin Bystol、Frederick Lahser、Rong Liu、Shiying Chen、Kung-I Feng、Mark Cartwright、Ernest Asante-Appiah、Joseph A. Kozlowski

  DOI：10.1021/acs.jmedchem.7b01927

  日期：2018.5.10

  We describe the discovery of MK-6169, a potent and pan-genotype hepatitis C virus NS5A inhibitor with optimized activity against common resistance-associated substitutions. SAR studies around the combination of changes to both the valine and aminal carbon region of elbasvir led to the discovery of a series of compounds with substantially improved potency against common resistance-associated substitutions in the major genotypes, as well as good pharmacokinetics in both rat and dog. Through further optimization of key leads from this effort, MK-6169 (21) was discovered as a preclinical candidate for further development.